Plasma Renin Activity (PRA) levels and antihypertensive drug use in a large healthcare system

American Journal of Hypertension

Volumn 25, Issue 3, 2012, Pages 379-388

  Sim, John J ^a   Bhandari, Simran K ^a   Shi, Jiaxiao ^b   Kalantar Zadeh, Kamyar ^c   Rasgon, Scott A ^a   Sealey, Jean E ^d   Laragh, John H ^d  

^a KAISER PERMANENTE MEDICAL CENTER   (United States)

^b Kaiser Permanente Southern California ^*  (United States)

^c HARBOR UCLA MEDICAL CENTER   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

blocker; ACEI; antihypertensive medications; ARB; blood pressure; CCB; diuretic; hypertension; plasma renin; PRA

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HORMONE RECEPTOR BLOCKING AGENT; LOOP DIURETIC AGENT; METHYLDOPA; MINERALOCORTICOID RECEPTOR; RENIN INHIBITOR; RESERPINE; THIAZIDE DIURETIC AGENT; URIC ACID;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DATA ANALYSIS; DATA BASE; DRUG USE; ETHNICITY; FEMALE; HEALTH CARE SYSTEM; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; UNITED STATES; UREA NITROGEN BLOOD LEVEL; URIC ACID BLOOD LEVEL;

ADOLESCENT; ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD UREA NITROGEN; CALCIUM CHANNEL BLOCKERS; CALIFORNIA; CROSS-SECTIONAL STUDIES; DIURETICS; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; POLYPHARMACY; RENIN; RENIN-ANGIOTENSIN SYSTEM; RETROSPECTIVE STUDIES; URIC ACID;

EID: 84857055789     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1038/ajh.2011.216     Document Type: Article

References (40)

1. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010; 303:2043-2050.
2. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003; 290:199-206. (Pubitemid 37430058)
3. Lloyd-Jones DM, Evans JC, Larson MG, O'Donnell CJ, Roccella EJ, Levy D. Differential control of systolic and diastolic blood pressure: factors associated with lack of blood pressure control in the community. Hypertension 2000; 36:594-599.
4. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360:1903-1913. (Pubitemid 35472129)
5. Whelton PK, He J, Appel LJ, Cutler JA, Havas S, Kotchen TA, Roccella EJ, Stout R, Vallbona C, Winston MC, Karimbakas J; National High Blood Pressure Education Program Coordinating Committee. Primary prevention of hypertension: clinical and public health advisory from The National High Blood Pressure Education Program. JAMA 2002; 288:1882-1888. (Pubitemid 35168144)
6. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51:1403-1419.
7. Sarafidis PA, Bakris GL. Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol 2008; 52:1749-1757.
8. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42:1206-1252. (Pubitemid 37553153)
9. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM; American Heart Association Professional Education Committee. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 117:e510-e526.
10. Furberg CD. Treatment of hypertension: a failing report card. Am J Hypertens 2009; 22:1-2.
11. Eide IK, Torjesen PA, Drolsum A, Babovic A, Lilledahl NP. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens 2004; 22:2217-2226. (Pubitemid 39463817)
12. Garg JP, Elliott WJ, Folker A, Izhar M, Black HR; RUSH University Hypertension Service. Resistant hypertension revisited: a comparison of two university-based cohorts. Am J Hypertens 2005; 18:619-626. (Pubitemid 40692429)
13. Laragh JH. Vasoconstriction-volume analysis for understanding and treating hypertension: the use of renin and aldosterone profiles. Am J Med 1973; 55: 261-274.
14. Laragh JH, Sealey JE. The plasma renin test reveals the contribution of body sodium-volume content (V) and renin-angiotensin (R) vasoconstriction to longterm blood pressure. Am J Hypertens 2011; 24:1164-1180.
15. Bidiville J, Nussberger J, Waeber G, Porchet M, Waeber B, Brunner HR. Individual responses to converting enzyme inhibitors and calcium antagonists. Hypertension 1988; 11:166-173. (Pubitemid 18086324)
16. Turner ST, Schwartz GL, Chapman AB, Beitelshees AL, Gums JG, Cooper-DeHoff RM, Boerwinkle E, Johnson JA, Bailey KR. Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension. Am J Hypertens 2010; 23:1014-1022.
17. Blumenfeld JD, Laragh JH. Renin system analysis: a rational method for the diagnosis and treatment of the individual patient with hypertension. Am J Hypertens 1998; 11:894-896. (Pubitemid 28351031)
18. Dickerson JE, Hingorani AD, Ashby MJ, Palmer CR, Brown MJ. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999; 353:2008-2013. (Pubitemid 29271745)
19. Alderman MH, Cohen HW, Sealey JE, Laragh JH. Pressor responses to antihypertensive drug types. Am J Hypertens 2010; 23:1031-1037.
20. Egan BM, Basile JN, Rehman SU, Davis PB, Grob CH 3rd, Riehle JF, Walters CA, Lackland DT, Merali C, Sealey JE, Laragh JH. Plasma Renin test-guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial. Am J Hypertens 2009; 22:792-801.
21. Furberg CD. Renin test-guided drug treatment of hypertension: the need for clinical trials. Am J Hypertens 2011; 24:1158-1163.
22. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130:461-470. (Pubitemid 29135798)
23. Bhandari SK, Pashayan S, Liu IL, Rasgon SA, Kujubu DA, Tom TY, Sim JJ. 25-hydroxyvitamin D levels and hypertension rates. J Clin Hypertens (Greenwich) 2011; 13:170-177.
24. Honda M, Hayashi K, Matsuda H, Kubota E, Tokuyama H, Okubo K, Ozawa Y, Saruta T. Divergent natriuretic action of calcium channel antagonists in mongrel dogs: renal haemodynamics as a determinant of natriuresis. Clin Sci 2001; 101:421-427. (Pubitemid 32929858)
25. Jones MR, Sealey JE, Laragh JH. Effects of angiotensin receptor blockers on ambulatory plasma Renin activity in healthy, normal subjects during unrestricted sodium intake. Am J Hypertens 2007; 20:907-916. (Pubitemid 47176356)
26. Sealey JE. Plasma renin activity and plasma prorenin assays. Clin Chem 1991; 37:1811-1819. (Pubitemid 121000617)
27. Gradman AH, Basile JN, Carter BL, Bakris GL; American Society of Hypertension Writing Group. Combination therapy in hypertension. J Am Soc Hypertens 2010; 4:42-50.
28. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981-2997.
29. Feldman RD, Zou GY, Vandervoort MK, Wong CJ, Nelson SA, Feagan BG. A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension 2009; 53:646-653.
30. Jamerson KA, Nwose O, Jean-Louis L, Schofield L, Purkayastha D, Baron M. Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension. Am J Hypertens 2004; 17:495-501. (Pubitemid 38726163)
31. Fung V, Huang J, Brand R, Newhouse JP, Hsu J. Hypertension treatment in a medicare population: adherence and systolic blood pressure control. Clin Ther 2007; 29:972-984. (Pubitemid 47223429)
32. Bramley TJ, Gerbino PP, Nightengale BS, Frech-Tamas F. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm 2006; 12:239-245. (Pubitemid 47400613)
33. Pittman DG, Tao Z, Chen W, Stettin GD. Antihypertensive medication adherence and subsequent healthcare utilization and costs. Am J Manag Care 2010; 16: 568-576.
34. Minami J, Ishimitsu T, Matsuoka H. Pretreatment plasma renin activity levels correlate with the blood pressure response to telmisartan in essential hypertension. Am J Hypertens 2008; 21:10-13.
35. Canzanello VJ, Baranco-Pryor E, Rahbari-Oskoui F, Schwartz GL, Boerwinkle E, Turner ST, Chapman AB. Predictors of blood pressure response to the angiotensin receptor blocker candesartan in essential hypertension. Am J Hypertens 2008; 21:61-66.
36. Blumenfeld JD. Plasma renin activity for predicting antihypertensive drug efficacy. Am J Hypertens 2008; 21:5-6.
37. Mulatero P, Rabbia F, Milan A, Paglieri C, Morello F, Chiandussi L, Veglio F. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension 2002; 40:897-902. (Pubitemid 35434913)
38. B̈ler FR, Laragh JH, Baer L, Vaughan ED Jr, Brunner HR. Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renindependent hypertensive diseases. N Engl J Med 1972; 287:1209-1214.
39. Sim JJ, Shi J, Calara F, Rasgon S, Jacobsen S, Kalantar-Zadeh K. Association of plasma renin activity and aldosterone-renin ratio with prevalence of chronic kidney disease: the Kaiser Permanente Southern California cohort. J Hypertens 2011; 29:2226-2235.
40. Sealey JE, Parra D, Rosenstein R, Laragh JH. "Effective" plasma renin activity: a derived measure for assessing residual plasma renin activity in patients taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Hypertension 2010; 55:e16; author reply e17.